Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

被引：0
|
作者：
Uzunbas, Gizem Karsli
McVeigh, Quinn
Gupta, Akansha
Hoyt, Stephanie
Doucette, Kristen
Keshishian, Hasmik
Carr, Steven
Yang, Xiaoping
Root, David
Cherniack, Andrew D.
Siegel, Franziska
Siegel, Stephan
Meyerson, Matthew
Greulich, Heidi
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-A037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Abstract A
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Uzunbas, Gizem Karsli
    McVeigh, Quinn
    Gupta, Akansha
    Hoyt, Stephanie
    Cherniack, Andrew
    Siegel, Franziska
    Siegel, Stephan
    Meyerson, Matthew
    Greulich, Heidi
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [2] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse
    Paul H. Huang
    [J]. Signal Transduction and Targeted Therapy, 4
  • [3] Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Vyse, Simon
    Huang, Paul H.
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [4] EGFR exon 20 insertion mutations in non-small cell lung cancer
    Wang, Fenfang
    Li, Chenghui
    Wu, Qihuan
    Lu, Hongyang
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2982 - 2991
  • [5] Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Wang, Mengzhao
    Yang, James Chih-Hsin
    Mitchell, Paul L.
    Fang, Jian
    Camidge, D. Ross
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Yang, Tsung-Ying
    Zhu, Viola W.
    Millward, Michael
    Fan, Yun
    Huang, Wen-Tsung
    Cheng, Ying
    Jiang, Liyan
    Brungs, Daniel
    Bazhenova, Lyudmila
    Lee, Chee Khoon
    Gao, Bo
    Xu, Yan
    Hsu, Wei-Hsun
    Zheng, Li
    Janne, Pasi A.
    [J]. CANCER DISCOVERY, 2022, 12 (07) : 1676 - 1689
  • [6] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
    David, Gil-Sierra Manuel
    del Pilar, Briceno-Casado Maria
    Cristina, Moreno-Ramos
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943
  • [7] Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer
    Huang, Wei-Sheng
    Li, Feng
    Gong, Yongjin
    Zhang, Yun
    Youngsaye, Willmen
    Xu, Yongjin
    Zhu, Xiaotian
    Greenfield, Matthew T.
    Kohlmann, Anna
    Taslimi, Paul M.
    Toms, Angela
    Zech, Stephan G.
    Zhou, Tianjun
    Das, Biplab
    Jang, Hyun G.
    Tugnait, Meera
    Ye, Yihua E.
    Gonzalvez, Francois
    Baker, Theresa E.
    Nadworny, Sara
    Ning, Yaoyu
    Wardwell, Scott D.
    Zhang, Sen
    Gould, Alexandra E.
    Hu, Yongbo
    Lane, Weston
    Skene, Robert J.
    Zou, Hua
    Clackson, Tim
    Narasimhan, Narayana I.
    Rivera, Victor M.
    Dalgarno, David C.
    Shakespeare, William C.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 80
  • [8] Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)
    Park, S.
    Kim, T. M.
    Kim, S.
    Kim, M.
    Keam, B.
    Kim, D. W.
    Heo, D. S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 174 : S110 - S111
  • [9] Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib
    Russell, Molly C.
    Garelli, Alyssa M.
    Reeves, David J.
    [J]. ANNALS OF PHARMACOTHERAPY, 2023, 57 (02) : 198 - 206
  • [10] The landscape of EGFR exon 20 insertion mutations in Chinese patients with non-small cell lung cancer.
    Xu, Shun
    Fu, Zhichao
    [J]. CANCER RESEARCH, 2022, 82 (12)
12345